Analysts Slash LENZ Therapeutics Price Target Following Earnings Miss

LENZ Therapeutics (NASDAQ: LENZ) faces downward pressure after its latest annual report failed to meet market expectations significantly. The company reported revenues of $19 million, while the statutory loss per share widened to $2.85, missing Wall Street estimates. In response, analysts lowered the consensus price target by 13% to $44.43, reflecting a more cautious outlook. Adding to the pressure, the company's stock price plummeted by nearly 20% this week as investor sentiment soured. A key factor in the sell-off is the slow market reception of VIZZ, the company's recently commercialized blurry vision treatment, which has yet to generate significant traction. This revision follows a broader trend of adjusting revenue and EPS forecasts downward for the biotech firm.

Sources:Simply Wall Streetmarketbeat.comintellectia.aibenzinga.comainvest.comfool.com